Interstitial Lung Disease News and Research

RSS
Interstitial lung disease (ILD) is a broad group of lung diseases comprising of more than a hundred distinct disorders. All of these involve scarring or inflammation of the interstitial lung tissue and affect the volume of oxygen that can reach the bloodstream via the respiratory system.
Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim and Duke expand collaboration to create largest patient registry for idiopathic pulmonary fibrosis (IPF)

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

Pulmonary hypertension impacts walking ability in SSc patients

Pulmonary hypertension impacts walking ability in SSc patients

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

M10 peptide could help protect systemic sclerosis patients against fibrotic damage

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

AstraZeneca reports new Phase I extended follow-up data on osimertinib in NSCLC patients at ELCC 2016

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

Understanding idiopathic pulmonary fibrosis: an interview with Michael Durheim, M.D.

Systemic sclerosis: an interview with Dr Kristin Highland

Systemic sclerosis: an interview with Dr Kristin Highland

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

AstraZeneca’s TAGRISSO (osimertinib) approved in EU for metastatic EGFR T790M mutation-positive NSCLC

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

Boehringer Ingelheim begins SENSCIS study to investigate safety, efficacy of nintedanib in patients with SSc-ILD

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

Pitt investigators to lead $15 million federal initiative to manage breathing disorder clinical trials

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

PFF, Veracyte partner on U.S. survey exploring patients' diagnostic experiences with interstitial lung diseases

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Updated guidelines released for treatment of idiopathic pulmonary fibrosis

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Pretreatment ILD is a risk factor for developing radiation pneumonitis in stage I NSCLC patients

Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Wolters Kluwer Health wins 12 prizes at 2014 BMA Medical Book Awards

Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Ornamental birds and exposure to pigeons may contribute to hypersensitive pneumonitis

Mortality predictors REVEALed for PAH in systemic sclerosis

Mortality predictors REVEALed for PAH in systemic sclerosis

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF

Phase III INPULSIS trials show nintedanib slows disease progression in patients with IPF